Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer.

International journal of molecular sciences - 5 Jan 2023

Bruggemann Liana, Falls Zackary, Mangione William, Schwartz Stanley A, Battaglia Sebastiano, Aalinkeel Ravikumar, Mahajan Supriya D, Samudrala Ram

Abstract excerpt

Pharmacogenomics is a rapidly growing field with the goal of providing personalized care to every patient. Previously, we developed the Computational Analysis of Novel Drug Opportunities (CANDO) platform for multiscale therapeutic discovery to screen optimal compounds for any indication/disease by performing analytics on their interactions using large protein libraries. We implemented a comprehensive precision...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Combinations

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Proteomics

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 36674513
DOI: 10.3390/ijms24020997
PMCID: PMC9867122

Genes

KRAS
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer.PMID 36674513Read ↗

MULTISCALE ANALYSIS AND VALIDATION OF EFFECTIVE DRUG COMBINATIONS TARGETING DRIVER KRAS MUTATIONS IN NON-SMALL CELL LUNG CANCERSemantic proximity Read ↗

Integrative omics analyses broaden treatment targets in human cancer.Semantic proximity Read ↗

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.Semantic proximity Read ↗

SIGNATURE-DRIVEN REPURPOSING OF MIDOSTAURIN FOR COMBINATION WITH MEK1/2 AND KRASG12C INHIBITORS IN LUNG CANCERSemantic proximity Read ↗

Expanding individualized therapeutic options via genoproteomics.Semantic proximity Read ↗

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergismsSemantic proximity Read ↗

Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer.Semantic proximity Read ↗

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to DiscoverySemantic proximity Read ↗

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.Semantic proximity Read ↗

Computational pharmacogenomics screen identifies synergistic statin-compound combinations as anti-breast cancer therapiesSemantic proximity Read ↗

SYNERGxDB: an integrative pharmacogenomic portal to identify synergistic drug combinations for precision oncology.Semantic proximity Read ↗

Combining cutting edge computational and experimental methods for targeting KRAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.